Sun Belt buyers hold the most power this spring
More homes for sale and more price cuts make this home shopping season more promising for buyers in many markets There are 5.5 engaged home shoppers for every for-sale... Read more.
TalentLMS and Epignosis Suite Remain the Only LMSs Fully GDPR-Compliant
SAN FRANSISCO, May 29, 2025 /PRNewswire/ — TalentLMS, along with the entire Epignosis eLearning suite, has renewed its compliance with the EU Cloud Code of... Read more.
QSE Group Provides Preview of Upcoming Website Redesign Focused on Optimized User Experience and Sales Flow
VANCOUVER, BC, May 29, 2025 /PRNewswire/ — Scope Technologies Corp. (CSE: SCPE) (OTCQB: SCPCF) (FSE: VN8) (“Scope Technologies” or the “Company”)... Read more.
Major Travel, Real Estate, Media Players Rely on Cordial’s AI to Win Customer Attention, Revenue
Industry Leaders BuzzFeed, HuffPost, Virgin Voyages, and Realtor.com® Transform Customer Experiences with Cordial SAN DIEGO, May 29, 2025 /PRNewswire/ — Cordial,... Read more.
Neema Unveils Dynamic Routing, Ensuring Seamless Transaction Flow and Optimization of Every Cross-Border Transaction for FX Rates, Efficiency and Speed
TEL AVIV, Israel, May 29, 2025 /PRNewswire/ — Neema, a pioneering global cross-border payments network catering to financial institutions, launched today Dynamic... Read more.
Diakonos Oncology to Present Phase I Results of Dubodencel (DOC1021), a Double-Loaded Dendritic Cell Therapy for Glioblastoma, at the ASCO 2025 Annual Meeting
HOUSTON, May 29, 2025 /PRNewswire/ — Diakonos Oncology Corp., a clinical-stage biotechnology company developing a new generation of immunotherapies to treat... Read more.
Buildots Raises $45 Million to Scale AI-Powered Operational Excellence in Construction
Investment brings total funding to $166M; will accelerate construction industry transformation amid booming mega-project construction TEL AVIV, Israel, May 29, 2025... Read more.
Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis, Moves Toward FDA Accelerated Approval
Meaningful efficacy observed in slow-progressor subgroup; NfL biomarker improvements support potential for accelerated regulatory pathway SEOUL, South Korea, May... Read more.
AccurEdit Therapeutics’ ART001 Becomes China’s First Gene Editing Therapy to Receive FDA Regenerative Medicine Advanced Therapy (RMAT) Designation
RMAT designation expected to expedite development; 72 weeks interim clinical trial data showing sustainable reduction of TTR over 90% with no significant adverse... Read more.
NeuLogiq® Platform Confirms Electrophysiological Marker of Target Engagement in Patients with Major Depressive Disorder
Data presented by Delix Therapeutics at the 2025 American Society of Clinical Psychopharmacology (ASCP) Conference confirms the NeuLogiq® Platform is effective... Read more.